Vortioxetine: A review of its use in major depressive disorder

CNS Drugs

Volumn 28, Issue 9, 2014, Pages 855-874

  Garnock Jones, Karly P ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ESCITALOPRAM; VENLAFAXINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ANXIETY; COGNITION; DISABILITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; EUROPEAN UNION; GERIATRIC PATIENT; HUMAN; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); ORAL CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; SHEEHAN DISABILITY SCALE; SHORT FORM 36; STEADY STATE; THERAPY; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; ANIMAL; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; SULFIDES;

EID: 84919883745     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0195-x     Document Type: Review

References (79)

1. American Psychiatric Association. Practice Guidelines for the treatment of major depressive disorder. 2010. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485. Accessed 19 June 2014.
2. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433-42.
3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
4. Lundbeck. Brintellix™ (vortioxetine hydrobromide tablets): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204447s000lbl.pdf. Accessed 20 June 2014.
5. Lundbeck. Brintellix™ (vortioxetine tablets): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002717/WC500159449.pdf. Accessed 20 June 2014.
6. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206-21.
7. Areberg J, Luntang-Jensen M, Søgaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401-4.
8. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190-8.
9. Sánchez C, Pehrson AL, Bétry C, et al. Vortioxetine (LU aa21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;9(Suppl. 1):106S-7S.
10. Sánchez C. Lu AA21004, a novel multimodal antidepressant. Neurotherapeutics. 2012;9(3):681-2.
11. Li Y, Pehrson AL, Budac DP, et al. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012;234(2):238-47.
12. Wilson S, Buchbjerg J, Højer AM, et al. Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study [abstract no. P.1.g.013]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S195-6.
13. Wang Y, Nomikos GG, Karim A, et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTC study. Clin Pharmacol Drug Dev. 2013;2(4):298-309.
14. Højer AM, Søgaard B, Areberg J. Investigation of the absorption profile of Lu AA21004 [abstract no. P 27]. Int J Psychiatry Clin Pract. 2011;15:25.
15. Pehrson AL, Cremers T, Bétry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133-45.
16. Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666-75.
17. Mørk A, Brennum L, Fallon S, et al. Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders [abstract no. P.2.d.017]. Eur Neuropsychopharmacol. 2009;19:S439.
18. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41-50.
19. Du Jardin KG, Liebenberg N, Muller H, et al. Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex [abstract no. P.2.e.001]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S392.
20. Pehrson A, Li Y, Haddjeri N, et al. Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms [abstract no. P.1.g.014]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S196-7.
21. Riga MS, Celada P, Sanchez C, et al. Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine [abstract no. P.2.e.003]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S393-4.
22. Dale E, Zhang H, Leiser SC, et al. Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus [abstract no. P.2.e.004]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S394.
23. Bétry C, Pehrson AL, Etiévant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2013;16(5):1115-27.
24. Guilloux J-P, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147-59.
25. Haddjeri N, Etievant A, Pehrson A, et al. Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition [abstract no. P.2.h.002]. Eur Neuropsychopharmacol. 2012;22(Suppl. 2):S303.
26. Leiser SC, Pehrson AL, Robichaud PJ, et al. Preclinical studies of the multimodal antidepressant vortioxetine support a potential for improvement of cognitive functions [abstract no. M157]. Neuropsychopharmacology. 2012;38:S164-5.
27. du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014;24(1):160-71.
28. Pehrson A, Plath N, Sanchez C. Vortioxetine (LU AA21004), an investigational multimodal antidepressant, reverses executive function deficits in rats treated subchronically with PCP [abstract no. NR11-56]. In: 166th annual meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
29. Theunissen EL, Street D, Højer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013;93(6):493-501.
30. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-23.
31. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014. doi: 10.1017/S1461145714000546.
32. Mahableshwarkar A, Zajecka J, Jacobson W, et al. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double-blind, active-referenced, placebo-controlled trial [abstract no. 016]. In: 29th CINP World Congress of Neuropsychopharmacology; 22-26 June 2014; Vancouver.
33. Areberg J, Sogaard B, Hojer A-M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111(3):198-205.
34. Mayer M, Xie J, Serenko M. Effect of formulation and food on the pharmacokinetics of Lu AA21004 in healthy subjects [abstract no. PII-49]. Clin Pharmacol Ther. 2012;91:S69-70.
35. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40(7):1357-65.
36. Dudkowski C, Lee R, Wu R, et al. A phase 1 study to assess the effect of age, gender and race on the pharmacokinetics of single and multiple doses of Lu AA21004 in healthy subjects [abstract no. PII-48]. Clin Pharmacol Ther. 2012;91:S69.
37. Wang Y, Munsaka M, Serenko M, et al. Evaluation of the single-dose pharmacokinetics of Lu AA21004 and its metabolites in subjects with and without hepatic impairment [abstract no. PIII-13]. Clin Pharmacol Ther. 2011;89(Suppl. 1):S71.
38. Chen G, Lee R, Hojer A-M, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727-36.
39. Chen G, Lee R, Zhao Z, et al. A Phase 1 study to assess the effect of LU AA21004 on the steady-state pharmacokinetics of lithium in healthy male subjects [abstract no. PI-84]. Clin Pharmacol Ther. 2012;91:S39.
40. Lee RD, Wang Y, Zhao Z, et al. Effects of multiple doses of Lu AA21004 on the steady-state pharmacokinetics and pharmacodynamics of warfarin [abstract no. 1122787]. J Clin Pharmacol. 2011;51(9):1346.
41. Chen G, Wang Y, Lee RD, et al. Effects of multiple doses of Lu AA21004 on the single-dose pharmacokinetics and pharmacodynamics of diazepam [abstract no. 1123287]. J Clin Pharmacol. 2011;51(9):1350.
42. Naik H, Chan S, Vakilynejad M, et al. A population pharmacokinetic (pk)-pharmacodynamic (pd) meta-analysis of vortioxetine (Lu AA21004) in patients with major depressive disorder (MDD) [abstract no. NR9-03 plus poster]. In: 166th Annual Meeting of the American Psychological Association; 18-22 May 2013; San Francisco.
43. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
44. Takeda. Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder [ClinicalTrials.gov identifier NCT 01255787]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.
45. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-91.
46. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-49.
47. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953-9.
48. Jacobsen P, Mahableshwarkar AR, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. In: 166th Annual Meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
49. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313-21.
50. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217-26.
51. Mahableshwarkar A, Jacobsen PL, Serenko M. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD [abstract no. NR9-01]. In: 166th Annual Meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
52. Mahableshwarkar A, Jacobsen PL, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. In: 166th Annual Meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
53. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408-16.
54. Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenalin reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014. doi: 10.1002/hup.2424.
55. Takeda. Safety and efficacy study of Lu AA21004 in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01179516]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.
56. Takeda. Efficacy and safety study of Lu AA21004 in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01163266]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.
57. Takeda. Safety and efficacy of vortioxetine (Lu AA21004) in adults with major depressive disorder [ClinicalTrials.gov identifier NCT01153009]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 20 June 2014.
58. Lundbeck H. Randomised placebo-controlled duloxetine-referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder [ClinicalTrials.gov identifier NCT00635219]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 30 June 2014.
59. Lundbeck H. Randomised placebo-controlled duloxetine-referenced study of efficacy and safety of 15 and 20 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults [ClinicalTrials.gov identifier NCT01140906]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 30 June 2014.
60. Takeda. Efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder [ClinicalTrials.gov identifier NCT00735709]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 7 July 2014.
61. Florea I, Danchenko N, Loft H, et al. The effect of vortioxetine (LU AA21004) on health-related quality of life (HRQOL) in patients with major depressive disorder (MDD) [abstract no. PMH55]. Value Health. 2013;16(3):A65.
62. Thase ME, Mahableshwarkar A, Dragheim M. The efficacy of vortioxetine vs. placebo in the treatment of adults with major depressive disorder: patient level data from 10 short-term studies and a meta-analysis [abstract no. T142]. Neuropsychopharmacology. 2013;38:S363-4.
63. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(1):60-82.
64. Wang G, Gislum M, Filippov G. Randomised, double-blind study of vortioxetine versus venlafaxine in adults with major depressive disorder (MDD) [abstract no. 033]. In: 29th CINP World Congress of Neuropsychopharmacology; 22-26 June 2014; Vancouver.
65. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717-24.
66. Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23(Suppl. 2):S325.
67. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013;29(1):36-44.
68. Jacobsen P, Harper L, Serenko M, et al. A phase 3, long-term, open-label extension study evaluating the safety and tolerability of 15 and 20 mg vortioxetine in subjects with major depressive disorder [abstract no. 017]. In: 29th CINP World Congress of Neuropsychopharmacology; 22-26 June 2014; Vancouver.
69. Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22(Suppl. 2):S255-6.
70. Jacobsen P, Mahableshwarkar AR, Chen Y, et al. Randomized, double-blind, head-to-head, flexible-dose study of vortioxetine vs escitalopram in sexual functioning in adults with well controlled major depressive disorder experiencing treatment-emergent sexual dysfunction [abstract no. 018]. In: 29th CINP World Congress of Neuropsychopharmacology; 22-26 June 2014; Vancouver.
71. European Medicines Agency. Vortioxetine: assessment report for an initial marketing authorisation application. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002717/WC500159447.pdf. Accessed 20 June 2014.
72. Gaudiano BA, Herbert JD. Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom. 2005;74(1):17-25.
73. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014;68(1):49-59.
74. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol. 2014;29(1):64-72.
75. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012;22(12):858-66.
76. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847-57.
77. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197-207.
78. Servier. Valdoxan (agomelatine tablets): EU summary of product characteristics. 2009. http://valdoxan.com/sites/default/files/Valdoxan%20SPC.pdf. Accessed 20 June 2014.
79. Whiting D, Cowen PJ. Drug information update: agomelatine. Psychiatr Online. 2013;37:356-8.